• Blood Centrifugation

    Sunstein prosecuted blood centrifugation patents for Haemonetics Corporation, a leader in the field of blood processing. The patented technologies allow blood components to be collected and processed for life-saving transfusions.

  • Purification

    Innovations by DEKA Research increase the efficiency of water purification systems, while reducing power and maintenance requirements. International patent applications like the one Sunstein prepared for DEKA can lead to worldwide adoption of a useful technology – one that can supply the developing world with access to safe water.

  • Shaft/hub

    Custom Machine & Tool Co. invented a novel shaft/hub connection device for precise component positioning and tight run-out control in demanding torque transmission applications such as timing-belt pulleys. Rigorous engineering analyses, as shown, demonstrate the benefits of CMT’s invention compared to other connection systems. The patent Sunstein obtained bolsters CMT’s position in a crowded marketplace.

  • Intravascular Stent

    Sunstein prosecuted a patent for a new stent that retains high radial strength but is more flexible and easier to insert into a patient’s coronary artery. The Crown™ stent is the product of our client DEKA’s collaboration with Cordis Corp., a Johnson & Johnson company, to improve the design of the Palmaz-Schatz® stent, the first intravascular stent proven to reduce blockage in arteries.

Deep Patent & Trial Experience

Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.

We participated in the representation of Ariad, obtaining a $65 million jury verdict for infringement of our client’s patents for regulating NF-kappaB cell-signaling activity, the largest verdict in Massachusetts that year.

Exergen Corporation vs. Kaz, USA, Inc.

Sunstein lawyers won a $14.6M verdict for patent infringement following a two-week jury trial for our client Exergen, the people who pioneered the temporal artery thermometer.

FairWarning IP, LLC v. Iatric, Inc.; FairWarning IP, LLC v. CynergisTek, Inc.

In both the District Court and at the Federal Circuit Court of Appeals, Sunstein successfully defended clients Iatric and CynergisTek against claims of patent infringement relating to software for detecting fraud and misuse of protected health information, obtaining judgments of patent invalidity under Section 101.

In disputes over brand names, we have also delivered major successes to our clients.

Winning at Post Grant Proceedings

Motorola Mobility LLC, Google Inc., and Apple Inc. v. Arendi S.A.R.L.

Motorola, Google and Apple attacked the same patent as Samsung raising several additional grounds. Our arguments carried the day and the inter partes review was not instituted, freeing our client’s patent for unfettered assertion in court.

Click here to learn more about Sunstein litigators.

Spotlight on Patents

A recent patent we obtained for our client Nexsan, of Santa Clara, CA,  U.S. Patent No. 9218406 covers a private cloud storage system in which security is maintained by storing the data on devices (sold under the Transporter brand) of  individual users.  Data is shared on a peer-to-peer basis.  A central  server governs access based on user privileges without storing any of  the shared data. This patent has issued in one of the fields in which recent court rulings have been propelling rapid evolution of the law.

In the News

Our Latest Thinking

  • Christopher Lacenere, Ph.D.

    PTAB Alert: On rare occasions, the Patent Trial and Appeal Board will reconsider its decision declining to institute an inter partes review (IPR). It helps if you can show that the judges misapplied a relevant legal doctrine.

    More...

  • Bruce D. Sunstein

    Through artful interpretation of the Supreme Court’s rigid guidelines in Alice (2014) for determining patent-eligibility, the Federal Circuit has recently offered patent protection to once seemingly endangered inventions.

    More...

  • Robert M. Asher

    Amending a patent claim in the midst of an inter partes review (IPR) is still hard for a patent owner, but the Federal Circuit has just made it a bit easier.

    More...

  • Thomas C. Carey

    Get your IPR arguments right the first time: The patent office sees objectionable unfairness in second-bite challenges to a patent’s validity.

    More...

  • Thomas J. Tuytschaevers

    Federal Circuit warns: If the patent office sees reason to reject patent claims for obviousness, it had better articulate that reason better than it has been accustomed to.

    More...

  • Brandon Scruggs

    The Eastern District of Texas has embraced its longtime status as a patent owner’s favorite trial court. The Federal Circuit has now cautioned that court to take seriously last summer’s Supreme Court decision restricting where corporations can be sued.

    More...

  • Thomas C. Carey

    An arbitration clause in a patent license cannot be avoided even when the licensee calls the patent’s validity into question.

    More...

  • Gozde Guckaya

    Read our roundup of IP cases on this season’s Supreme Court docket.

    More...

Free Subscription

See more in Publications/News